Acquired RAS or EGFR mutations and duration of response to EGFR blockade in colorectal cancer
Open accessThe DOI matches its Crossref record; 47 of the 48 references it cites were found in a registry or an index.
Abstract
Blockade of the epidermal growth factor receptor (EGFR) with the monoclonal antibodies cetuximab or panitumumab is effective in a subset of colorectal cancers (CRCs), but the emergence of resistance limits the efficacy of these therapeutic agents. At relapse, the majority of patients develop RAS mutations, while a subset acquires EGFR extracellular domain (ECD) mutations. Here we find that patients who experience greater and longer responses to EGFR blockade preferentially develop EGFR ECD mutations, while RAS mutations emerge more frequently in patients with smaller tumour shrinkage and shorter progression-free survival. In circulating cell-free tumour DNA of patients treated with anti-EGFR antibodies, RAS mutations emerge earlier than EGFR ECD variants. Subclonal RAS but not EGFR ECD mutations are present in CRC samples obtained before exposure to EGFR blockade. These data indicate that clonal evolution of drug-resistant cells is associated with the clinical outcome of CRC patients treated with anti-EGFR antibodies.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Figures





Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
The source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“Preexisting RAS mutations driving EGFR-independent signaling are seen in intrinsic resistance, whereas the emergence of secondary KRAS mutations or resistant subclonal populations’ expansion during treatment is observed in acquired resistance [13].”
From Overcoming Resistance to Anti-EGFR Therapies: Mechanisms of Cetuximab and Panitumumab Resistance and Emerging Combination Strategies (2026) · cites this paper as [13]
Experimental — accuracy not yet measuredThe source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“EGFR somatic sequence changes, including G465R, G465E, S468R and S492R, located at the extracellular domains (ECDs) of the EGFR-mAb interaction interface, confer resistance to cetuximab and panitumumab by preventing mAb binding [10, 67, 68].”
From Resistance to anti-EGFR therapies in metastatic colorectal cancer: underlying mechanisms and reversal strategies (2021) · cites this paper as [67]
Experimental — accuracy not yet measuredIn the citing paper
“A growing number of studies suggest that mutations in the extracellular domain (ECD) of the EGFR, such as S492R, G465E, R451C and K467T, prevent binding cetuximab and make CRC resistant to anti-EGFR mAbs [141,142,143,144].”
From Drug Resistance in Colorectal Cancer: From Mechanism to Clinic (2022) · cites this paper as [143]
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Basic local alignment search tool
Altschul, S. F., Gish, W., Miller, W., Myers, E. W., & Lipman, D. J. (1990) · Journal of Molecular Biology · doi:10.1006/jmbi.1990.9999 · Cited by 98,669
The Sequence Alignment/Map format and SAMtools
Li, H., Handsaker, B., Wysoker, A., Fennell, T., Ruan, J., Homer, N., Marth, G., Abecasis, G., Durbin, R., & 1000 Genome Project Data Processing Subgroup (2009) · Bioinformatics · doi:10.1093/bioinformatics/btp352 · Cited by 62,041
Fast and accurate short read alignment with Burrows-Wheeler transform
Li, H., & Durbin, R. (2009) · Bioinformatics · doi:10.1093/bioinformatics/btp324 · Cited by 58,607
New response evaluation criteria in solid tumours: revised RECIST guideline (version 1.1)
Eisenhauer, E. A., Therasse, P., Bogaerts, J., Schwartz, L. H., Sargent, D., Ford, R., Dancey, J., Arbuck, S., Gwyther, S., Mooney, M., et al. (2009) · European Journal of Cancer · doi:10.1016/j.ejca.2008.10.026 · Cited by 29,534
Fast and accurate long-read alignment with Burrows-Wheeler transform.
Li, H., & Durbin, R. (2010) · Bioinformatics · doi:10.1093/bioinformatics/btp698 · Cited by 12,063
<tt>BLAT</tt> —The <tt>BLAST</tt> -Like Alignment Tool
Kent, W. J. (2002) · Genome Research · doi:10.1101/gr.229202 · Cited by 8,480
The emerging hallmarks of cancer metabolism
Pavlova, N. N., & Thompson, C. B. (2016) · Cell Metabolism · doi:10.1016/j.cmet.2015.12.006 · Cited by 5,926
Cunningham, D., Humblet, Y., Siena, S., Khayat, D., Bleiberg, H., Santoro, A., Bets, D., Mueser, M., Harstrick, A., Verslype, C., et al. (2004) · New England Journal of Medicine · doi:10.1056/nejmoa033025 · Cited by 5,035
Self-citationMET Amplification Leads to Gefitinib Resistance in Lung Cancer by Activating ERBB3 Signaling
Engelman, J. A., Zejnullahu, K., Mitsudomi, T., Song, Y., Hyland, C., Park, J. O., Lindeman, N., Gale, C.-M., Zhao, X., Christensen, J., et al. (2007) · Science · doi:10.1126/science.1141478 · Cited by 4,496
Pao, W., Miller, V. A., Politi, K. A., Riely, G. J., Somwar, R., Zakowski, M. F., Kris, M. G., & Varmus, H. (2005) · PLoS Medicine · doi:10.1371/journal.pmed.0020073 · Cited by 3,527
Research works printed but not linked: 1
- Whitehead, R. H., Macrae, F. A., St Sohn, D. J. & Ma, J. A colon cancer cell line (LIM1215) derived from a patient with inherited nonpolyposis colorectal cancer. J. Natl Cancer Inst. 74, 759–765 (1985).
Cited by
Items 101–200 of 221
Monitoring resistance through liquid biopsy
Parikh, A. R., & Corcoran, R. B. (2017) · Annals of Oncology · doi:10.1093/annonc/mdx650 · Cited by 23
Predictive Biomarkers in Metastatic Colorectal Cancer: A Systematic Review
Bañobre, J. R., Kandimalla, R., & Goel, A. (2019) · JCO Precision Oncology · doi:10.1200/po.18.00260 · Cited by 29
Milton, C. K., Self, A. J., Clarke, P. A., Banerji, U., Piccioni, F., Root, D. E., & Whittaker, S. R. (2020) · Molecular Cancer Therapeutics · doi:10.1158/1535-7163.mct-19-1131 · Cited by 24
Clonal evolution and expansion associated with therapy resistance and relapse of colorectal cancer
Anupriya, S., Chakraborty, A., & Patnaik, S. (2022) · Mutation Research/Reviews in Mutation Research · doi:10.1016/j.mrrev.2022.108445 · Cited by 26
Cremolini, C., Montagut, C. O., Ronga, P., Venturini, F., Yamaguchi, K., Stintzing, S., & Sobrero, A. F. (2023) · Frontiers in Oncology · doi:10.3389/fonc.2022.946850 · Cited by 25
Self-citationDucreux, M. P., Tabernero, J. M., Grothey, A. F., Arnold, D., O'Dwyer, P. J., Gilberg, F., Abbas, A. R., Thakur, M. D., Prizant, H., Irahara, N., et al. (2023) · European Journal of Cancer · doi:10.1016/j.ejca.2023.01.023 · Cited by 20
Is Precision Medicine an Oxymoron?
Eckhardt, S. G., & Lieu, C. H. (2018) · JAMA Oncology · doi:10.1001/jamaoncol.2018.5099 · Cited by 20
Zhuang, X., Wang, Z., Fan, J., Bai, X., Xu, Y., Chou, J. J., Hou, T., Chen, S., & Pan, L. (2022) · Nature Communications · doi:10.1038/s41467-022-32159-6 · Cited by 27
Ako, S., Nouso, K., Kinugasa, H., Matsushita, H., Terasawa, H., Adachi, T., Wada, N., Takeuchi, Y., Mandai, M., Onishi, H., et al. (2020) · Oncology · doi:10.1159/000506135 · Cited by 21
Chen, C. T., Bartolomeo, M. D., Corallo, S., Strickler, J. H., & Goyal, L. (2020) · American Society of Clinical Oncology Educational Book · doi:10.1200/edbk_280871 · Cited by 20
Ren, S.-N., Zhang, Z.-Y., Guo, R.-J., Wang, D., Chen, F., Chen, X., & Fang, X. (2023) · World Journal of Gastroenterology · doi:10.3748/wjg.v29.i13.1911 · Cited by 22
Adua, D., Fabio, F. D., Ercolani, G., Fiorentino, M., Gruppioni, E., Altimari, A., Llimpe, F. L. R., Normanno, N., Pinna, A. D., & Pinto, C. (2017) · Molecular and Clinical Oncology · doi:10.3892/mco.2017.1270 · Cited by 18
Karani, A., Felismino, T. C., Diniz, L. A., de Macêdo, M. P., Silva, V. S. E., & de Mello, C. A. L. (2020) · ecancermedicalscience · doi:10.3332/ecancer.2020.1069 · Cited by 18
Plasma KRAS mutations predict the early recurrence after surgical resection of pancreatic cancer
Ako, S., Kato, H., Nouso, K., Kinugasa, H., Terasawa, H., Matushita, H., Takada, S., Saragai, Y., Mizukawa, S., Muro, S., et al. (2021) · Cancer Biology & Therapy · doi:10.1080/15384047.2021.1980312 · Cited by 18
The Position of Circulating Tumor DNA in the Clinical Management of Colorectal Cancer
de Abreu, A. R., de Beeck, K. O., Laurent‐Puig, P., Taly, V., & Benhaïm, L. (2023) · Cancers · doi:10.3390/cancers15041284 · Cited by 22
Li, Y., Han, L., Hong, H., Li, D., Gong, L., Zhao, J., Wang, Z., & Wu, Z. (2024) · Advanced Science · doi:10.1002/advs.202307613 · Cited by 18
Bovio, F., Epistolio, S., Mozzi, A., Monti, E., Fusi, P. A., Forcella, M. E., & Frattini, M. (2020) · International Journal of Molecular Sciences · doi:10.3390/ijms21228805 · Cited by 17
Harris, K. L., Myers, M. B., McKim, K. L., Elespuru, R. K., & Parsons, B. L. (2019) · Environmental and Molecular Mutagenesis · doi:10.1002/em.22326 · Cited by 18
Towards Circulating-Tumor DNA-Based Precision Medicine
Hironaka‐Mitsuhashi, A., Calle, A. S., Ochiya, T., Takayama, S., & Suto, A. (2019) · Journal of Clinical Medicine · doi:10.3390/jcm8091365 · Cited by 16
Drouet, Y., Treilleux, I., Viari, A., Goddard‐Léon, S., Devouassoux‐Shisheboran, M., Voirin, N., de la Fouchardière, C., Manship, B. M., Puisieux, A., Lasset, C., et al. (2018) · Scientific Reports · doi:10.1038/s41598-018-25631-1 · Cited by 18
Colorectal Cancer Modeling with Organoids: Discriminating between Oncogenic RAS and BRAF Variants
Post, J. B., Roodhart, J. M. L., & Snippert, H. J. G. (2020) · Trends in cancer · doi:10.1016/j.trecan.2019.12.005 · Cited by 18
Vangala, D., Ladigan, S., Liffers, S. T., Noseir, S., Maghnouj, A., Götze, T.-M., Verdoodt, B., Klein‐Scory, S., Godfrey, L., Zowada, M. K., et al. (2021) · Genome Medicine · doi:10.1186/s13073-021-00926-7 · Cited by 17
Zhuang, Q.-S., Sun, X., Chong, Q.-Y., Banerjee, A., Zhang, M., Wu, Z., Zhu, T., Pandey, V., & Lobie, P. E. (2021) · Frontiers in Oncology · doi:10.3389/fonc.2021.712348 · Cited by 14
Roazzi, L., Patelli, G., Bencardino, K. B., Amatu, A., Bonazzina, E. F., Tosi, F., Amoruso, B., Bombelli, A., Mariano, S., Stabile, S., et al. (2024) · Clinical Colorectal Cancer · doi:10.1016/j.clcc.2024.02.001 · Cited by 17
Self-citationLiquid biopsy entering clinical practice: Past discoveries, current insights, and future innovations
Song, J., Xiong, Y., & Xiao, H. F. (2025) · Critical Reviews in Oncology/Hematology · doi:10.1016/j.critrevonc.2025.104613 · Cited by 19
Lampropoulou, D. I., Aravantinos, G., Katifelis, H., Lazaris, F. S., Laschos, Κ., Theodosopoulos, T., PAPADIMITRIOU, C. A., & Gazouli, M. (2019) · Cancer Biomarkers · doi:10.3233/cbm-182383 · Cited by 14
Dynamic Treatment Stratification Using ctDNA
Vidal, J., Taus, Á., & Montagut, C. O. (2019) · Recent results in cancer research/Recent Results in Cancer Research · doi:10.1007/978-3-030-26439-0_14 · Cited by 14
Self-citationGenomic and epigenomic biomarkers in colorectal cancer: From diagnosis to therapy
Bañobre, J. R., & Goel, A. (2021) · Advances in cancer research · doi:10.1016/bs.acr.2021.02.008 · Cited by 20
Ardito, F., Razionale, F., Salvatore, L., Cenci, T., Vellone, M., Basso, M., Panettieri, E., Calegari, M. A., Tortora, G., Martini, M., et al. (2021) · Cancers · doi:10.3390/cancers13092148 · Cited by 15
Mapping intratumor heterogeneity across layers for advancing immunotherapy
Marine, J., Bartok, O., Sagie, S., Vitiello, P. P., Bardelli, A., Weller, C., Chang, T., Tonelli, C., Spranger, S., Ruppin, E., et al. (2026) · Cell · doi:10.1016/j.cell.2026.03.025 · Cited by 16
Self-citationClinical Application of Liquid Biopsy in Targeted Therapy of Metastatic Colorectal Cancer
Trojan, J., Klein‐Scory, S., Koch, C., Schmiegel, W., & Baraniskin, A. (2017) · Case Reports in Oncological Medicine · doi:10.1155/2017/6139634 · Cited by 13
Mechanisms of resistance to EGFR-targeted therapies in colorectal cancer: more than just genetics
Parseghian, C. M., Eluri, M., Kopetz, S., & Raghav, K. P. S. (2023) · Frontiers in Cell and Developmental Biology · doi:10.3389/fcell.2023.1176657 · Cited by 16
Merlini, A., Centomo, M. L., Ferrero, G., Chiabotto, G., Miglio, U., Berrino, E., Giordano, G., Brusco, S., Pisacane, A. M., Maldi, E., et al. (2022) · Frontiers in Oncology · doi:10.3389/fonc.2022.844250 · Cited by 14
Self-citationLiquid biopsy, a paradigm shift in oncology: what interventional radiologists should know
Calandri, M., Siravegna, G., Yevich, S. M., Stranieri, G., Gazzera, C., Kopetz, S., Fonio, P., Gupta, S. K., Bardelli, A., Veltri, A., et al. (2020) · European Radiology · doi:10.1007/s00330-020-06700-4 · Cited by 13
Self-citationJi, J., Wang, C., & Fakih, M. (2021) · Clinical Colorectal Cancer · doi:10.1016/j.clcc.2021.12.001 · Cited by 16
Pharmacological Targeting of Epithelial-to-Mesenchymal Transition in Colorectal Cancer
Zafari, N., Velayati, M., Nassiri, M., Khazaei, M., Hassanian, S. M., Ferns, G. A., & Avan, A. (2022) · Current Pharmaceutical Design · doi:10.2174/1381612828666220728152350 · Cited by 13
Harrold, E. C., Keane, F., Walch, H. S., Chou, J. F., Sinopoli, J. C., Palladino, S., Al-Rawi, D. H., Chadalavada, K., Manca, P., Chalasani, S. B., et al. (2024) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-23-4005 · Cited by 13
Comprehensive review of signaling pathways and therapeutic targets in gastrointestinal cancers
Ji, P., Chen, T., Li, C. R., Zhang, J., Li, X., & Zhu, H. P. (2024) · Critical Reviews in Oncology/Hematology · doi:10.1016/j.critrevonc.2024.104586 · Cited by 11
SRSF3 Promotes Angiogenesis in Colorectal Cancer by Splicing SRF
Chen, Y., Yang, M. G., Meng, F., Zhang, Y., Wang, M., Guo, X., Yang, J., Zhang, H., Zhang, H., Sun, J., et al. (2022) · Frontiers in Oncology · doi:10.3389/fonc.2022.810610 · Cited by 11
Thomsen, C. B., Andersen, R. F., Lindebjerg, J., Hansen, T. F., Jensen, L. H., & Jakobsen, A. K. M. (2018) · Clinical Colorectal Cancer · doi:10.1016/j.clcc.2018.10.004 · Cited by 11
Yang, W., Zou, J., Li, Y., Liu, R., Yan, Z., Chen, S., Zhao, X., Guo, W., Huang, M., Li, W., et al. (2022) · Frontiers in Oncology · doi:10.3389/fonc.2022.830816 · Cited by 15
Yang, S., Gu, C., Miao, X., Zuo, H., Xu, W. L., Zhang, Y., Tang, W., Zhu, J., Yuan, Z., Gu, X., et al. (2025) · Journal for ImmunoTherapy of Cancer · doi:10.1136/jitc-2025-013763 · Cited by 12
Kitagawa, Y., Okumura, K., Watanabe, T., Tsukamoto, K., Kitano, S., Nankinzan, R., Suzuki, T., Hara, T., Soda, H., Denda, T., et al. (2019) · Scientific Reports · doi:10.1038/s41598-019-47700-9 · Cited by 10
Chen, K., Wang, H., Collins, G. P., Hollands, E. C., Law, I. Y. J., & Toh, J. W. T. (2022) · Current Oncology · doi:10.3390/curroncol29030116 · Cited by 11
Rachiglio, A. M., Forgione, L., Pasquale, R., Barone, C. A., Maiello, E., Antonuzzo, L., Cassata, A., Tonini, G., Bordonaro, R., Rosati, G., et al. (2022) · Cancers · doi:10.3390/cancers14041052 · Cited by 11
Wang, D., Wang, L., Zheng, L., Chen, J., Zhang, W., Zhou, W., Yang, X., Jiang, L., Jin, X., Yu, X., et al. (2023) · Advanced Healthcare Materials · doi:10.1002/adhm.202202989 · Cited by 9
Cell-Free DNA in the Management of Colorectal Cancer
Harlé, A. (2019) · Recent results in cancer research/Recent Results in Cancer Research · doi:10.1007/978-3-030-26439-0_13 · Cited by 8
An oncospace for human cancers
Aguadé‐Gorgorió, G., Costa, J. C., & Solé, R. V. (2023) · BioEssays · doi:10.1002/bies.202200215 · Cited by 7
Bioluminescence-based assays for quantifying endogenous protein interactions in live cells
Niles, A. L., Dibble, M., Machleidt, T., Martino, K., Swiatnicki, M., Vu, E. H., & Schwinn, M. K. (2025) · Journal of Biological Chemistry · doi:10.1016/j.jbc.2025.110454 · Cited by 7
Mirandola, A., Kudriavtsev, A., Muñoz, C. I. C., Comas, R., Macagno, M., Daoud, S., Sánchez, C., Pastor, B., Pisareva, E., Marin, M. S., et al. (2024) · EBioMedicine · doi:10.1016/j.ebiom.2024.105352 · Cited by 8
Self-citationWu, C., Liu, X., Liu, R., Song, S., Zheng, Z., Zeng, Y., Mei, Y., Zhang, J., Duan, Q.-J., Lin, R., et al. (2024) · Advanced Science · doi:10.1002/advs.202407239 · Cited by 9
Ozeki, Y., Kanogawa, N., Ogasawara, S., Ogawa, K., Ishino, T., Nakagawa, M., Fujiwara, K., Unozawa, H., Iwanaga, T., Sakuma, T., et al. (2022) · International Journal of Clinical Oncology · doi:10.1007/s10147-022-02195-9 · Cited by 7
D'Onofrio, R., Caputo, F., Prampolini, F., Spallanzani, A., Gelsomino, F., Bettelli, S. R., Manfredini, S., Bonetti, L. R., Carotenuto, P., Bocconi, A., et al. (2022) · Tumori Journal · doi:10.1177/03008916221122554 · Cited by 7
Ou, F., Ahn, D. H., Dixon, J. G., Grothey, A. F., Lou, Y., Kasi, P. M., Hubbard, J. M., Cutsem, E. V., Saltz, L. B., Schmoll, H., et al. (2023) · Cancers · doi:10.3390/cancers15164117 · Cited by 6
Liquid Biopsies in Colorectal Cancer: Monitoring Genetic Heterogeneity
Gargalionis, A. N., & Papavassiliou, A. G. (2017) · Trends in cancer · doi:10.1016/j.trecan.2017.01.003 · Cited by 7
Dissecting and analyzing the Subclonal Mutations Associated with Poor Prognosis in Diffuse Glioma
Bai, M., Wang, X., Zhang, H., Wang, J., Lyaysan, G., Xu, S., Tian, K., Wang, T., Li, J., Wang, N., et al. (2022) · BioMed Research International · doi:10.1155/2022/4919111 · Cited by 7
Trivedi, T. S., Shaikh, A. M., Mankad, A., Rawal, R., & Patel, S. (2023) · Biochemical Genetics · doi:10.1007/s10528-023-10575-7 · Cited by 7
Homeopathy, Fundamentalism, and the Memory of Water
Milgrom, L. R. (2007) · Current Oncology · doi:10.3747/co.2007.161 · Cited by 8
Lastraioli, E., Bettiol, A., Iorio, J., Limatola, E., Checcacci, D., Parisi, E., Bianchi, C., Arcangeli, A., Iannopollo, M., Costanzo, F. D., et al. (2023) · Cells · doi:10.3390/cells12111458 · Cited by 5
Moradi‐Marjaneh, R., Asgharzadeh, F., Khordad, E., & Marjaneh, M. M. (2020) · Current Pharmaceutical Design · doi:10.2174/1381612826666201007163116 · Cited by 6
Kastrisiou, M., Zarkavelis, G., Kougioumtzi, A., Sakaloglou, P., Kostoulas, C., Georgiou, I. A., Batistatou, A. K., Pentheroudakis, G. E., & Magklara, A. (2021) · Diagnostics · doi:10.3390/diagnostics11122375 · Cited by 9
Popescu, I., Croitoru, V. M., Croitoru-Cazacu, I. M., Dudau, A.-M., Herlea, V., Dima, S. O., & Croitoru, A. E. (2024) · Journal of Personalized Medicine · doi:10.3390/jpm14070750 · Cited by 4
“This phenomenon has been confirmed in several reports, although the rate of patients who become RAS-mutant at progression significantly differs among the various studies [10,15,22,30,51–54].”
ResultPan-RAS inhibitors and polo-like kinase 1: promising targets in colorectal cancer
Jayachandran, P., Elliott, A., Soni, S., Battaglin, F., Mittal, P., Algaze, S. D., Lo, J. H., Yang, Y., Ashouri, K., Torres, E. T. R., et al. (2025) · Oncogene · doi:10.1038/s41388-025-03484-z · Cited by 6
Panitumumab Alone for Maintenance Treatment in Advanced Colorectal Cancer
Anandappa, G., & Cunningham, D. (2019) · JAMA Oncology · doi:10.1001/jamaoncol.2019.1447 · Cited by 4
The impact of RAS mutation on the treatment strategy of colorectal cancer
Pirvu, E. E., Severin, E. M., Niţă, I., & Toma, Ş. A. (2023) · Medicine and Pharmacy Reports · doi:10.15386/mpr-2408 · Cited by 5
Engineered Nanomedicines for Augmenting the Efficacy of Colorectal Cancer Immunotherapy
Abdelgalil, R. M., Elmorshedy, Y. M., Elkhodairy, K. A., Teleb, M., Bekhit, A. A., Khattab, S. N., & Elzoghby, A. O. (2022) · Nanomedicine · doi:10.2217/nnm-2022-0214 · Cited by 6
Sur, D. G., Lungulescu, C., Dumitrescu, E. A., Afrăsânie, V. A., Spînu, Ș., Lungulescu, C. V., & Schmoll, H. (2023) · Expert Review of Anticancer Therapy · doi:10.1080/14737140.2023.2207830 · Cited by 4
Long, X., Liu, X., Xia, W., Liu, L., & Chen, W. (2024) · Frontiers in Bioscience-Landmark · doi:10.31083/j.fbl2905174 · Cited by 6
Kawczak, P., & Bączek, T. (2026) · Journal of Clinical Medicine · doi:10.3390/jcm15062387 · Cited by 6
Recent progress in metal-based drugs for colorectal cancer therapy
Liu, X., Zhang, Q., Yang, X., Liang, J., He, Y., Chao, H., & Pan, Y. (2026) · Coordination Chemistry Reviews · doi:10.1016/j.ccr.2026.217971 · Cited by 3
Liquid Biopsy in Advanced Colorectal Cancer: Clinical Applications of Different Analytes
Delcuratolo, M. D., Modrego-Sánchez, A., Bungaro, M., Antón-Pascual, B., Terán, S., Dipace, V., Novello, S., García‐Carbonero, R., Passiglia, F., & Graválos-Castro, C. (2023) · Journal of Molecular Pathology · doi:10.3390/jmp4030013 · Cited by 5
Oligo-Metastatic Disease in Oncology: Exploring the Limits and the Potential of Genetic Assessment
Santorsola, M., Capuozzo, M., Savarese, G., Ianniello, M., Petrillo, N., Casillo, M., Sabbatino, F., Perri, F., Ferrara, F., Zovi, A., et al. (2023) · Genes · doi:10.3390/genes14122131 · Cited by 3
Petit, J. A., Carroll, G. M., Zhao, J., Pockney, P. G., & Scott, R. J. (2024) · Gastroenterology Insights · doi:10.3390/gastroent15010008 · Cited by 3
Oldani, M., Guzzetti, L., Pioltelli, E., Sala, D., Panzeri, D., Brioschi, M., Forcella, M. E., & Fusi, P. A. (2025) · Molecular Nutrition & Food Research · doi:10.1002/mnfr.70018 · Cited by 3
Bianchi, A. S., & Siena, S. (2017) · Handbook of experimental pharmacology · doi:10.1007/164_2017_19 · Cited by 3
Self-citationEGFR and FGFR in Growth and Metastasis of Colorectal Cancer
Dariya, B., Merchant, N., Aliya, S., Alam, A., & Nagaraju, G. P. (2018) · Springer eBooks · doi:10.1007/978-981-13-1486-5_11 · Cited by 3
S645C Point Mutation Suppresses Degradation of EGFR to Promote Progression of Glioblastoma
Huang, W., Zou, L., Hao, Z., Wang, B., Mao, F., Duan, Q., & Guo, D. (2022) · Frontiers in Oncology · doi:10.3389/fonc.2022.904383 · Cited by 3
Heterogeneous disease and intermittent treatment in metastatic colorectal cancer: A case report
Stefano, A. D., Zanaletti, N., Cassata, A., Silvestro, L., Nappi, A. G., Casaretti, R., Romano, C., Foschini, F., Cardone, C., Borrelli, M., et al. (2023) · Frontiers in Oncology · doi:10.3389/fonc.2023.1084681 · Cited by 3
Opportunities for Liquid Biopsies to Meet the Challenges of Precision Medicine
Kelloff, G. J., & Sigman, C. C. (2023) · Current cancer research · doi:10.1007/978-3-031-22903-9_17 · Cited by 4
Colorectal cancer: understanding of disease
Mohapatra, L., Tripathi, A. S., Mishra, D. K., Yasir, M., Maurya, R. K., Prajapati, B. G., & Alka (2024) · Elsevier eBooks · doi:10.1016/b978-0-443-13870-6.00010-6 · Cited by 4
Current Utility and Future Applications of ctDNA in Colorectal Cancer
Day, D., Frentzas, S., Naidu, C. A., Segelov, E., & Green, M. M. (2019) · IntechOpen eBooks · doi:10.5772/intechopen.82316 · Cited by 3
Guerrera, L. P., Napolitano, S., Falco, V. D., Giunta, E. F., Vitiello, P. P., Gravina, A. G., Suarato, G., Perrone, A., Napolitano, R., Martinelli, E., et al. (2021) · Clinical Colorectal Cancer · doi:10.1016/j.clcc.2021.07.005 · Cited by 3
Post, J. B., Hami, N., Lohuis, J. O., van de Ven, M., de Korte‐Grimmerink, R., Stangl, C., Stelloo, E., Verlaan-Klink, I., van Rheenen, J., & Snippert, H. J. G. (2019) · bioRxiv (Cold Spring Harbor Laboratory) · doi:10.1101/860122 · Cited by 5
Cheng, P., Lan, Y., Liao, J., Zhao, E., Yan, H., Xu, L., Suru, A., Ping, Y., & Xu, J. (2022) · Genomics · doi:10.1016/j.ygeno.2022.110412 · Cited by 2
SCG2 Mediates HNSCC Progression With CCL2 / TGFβ1 high M2 Macrophage Infiltration
Miao, C., You, X., Zhang, Z., Jiang, Z., Liu, L., Jia, Y., Bai, J., Gao, Y., Ye, L., Cao, Y., et al. (2024) · Oral Diseases · doi:10.1111/odi.15154 · Cited by 5
Integrating artificial intelligence ( AI ) into colorectal cancer reporting
Bräutigam, K., Baker, A., Koelzer, V. H., Kather, J. N., & Graham, T. A. (2026) · The Journal of Pathology · doi:10.1002/path.70029 · Cited by 4
Novel bispecific T-cell engagers overcoming acquired EGFR resistance
Kühl, L., Löffler, A.-K., Seifert, O., Michler, D., Kuhlmann, M., Russo, G., Kuhn, P., Nowack, H., Frenzel, A., Schirrmann, T., et al. (2026) · mAbs · doi:10.1080/19420862.2026.2674236 · Cited by 2
Jafarlou, M., Jafarlou, V., Nouri, S., Alizadeh, N., Tabrizi, Z. A., Iravani, M., Ghorbaninezhad, F., Shakiba, D., & Baradaran, B. (2026) · Cancer Cell International · doi:10.1186/s12935-026-04385-1 · Cited by 3
Molecular mechanisms of resistance to the EGFR monoclonal antibody cetuximab
Ma, Z., Lei, C., & Hu, S. (2023) · Elsevier eBooks · doi:10.1016/b978-0-12-821584-5.00007-9 · Cited by 2
Aberrant Signaling Pathways in Cancer
Grumolato, L., & Aaronson, S. A. (2022) · Wiley eBooks · doi:10.1002/9781119000822.hfcm010.pub2 · Cited by 3
Editorial: The impact of genetics on CRC therapy: from adaptive mutability to drug resistance
Crisafulli, G., & Siravegna, G. (2023) · Frontiers in Oncology · doi:10.3389/fonc.2023.1260158 · Cited by 2
Self-citationHenrykowska, G., Bartusik-Aebisher, D., Dynarowicz, K., Ramesh, T. S., Smolak, B., & Aebisher, D. (2026) · Pharmaceuticals · doi:10.3390/ph19071041 · Cited by 1
“Preexisting RAS mutations driving EGFR-independent signaling are seen in intrinsic resistance, whereas the emergence of secondary KRAS mutations or resistant subclonal populations’ expansion during treatment is observed in acquired resistance [13].”
Modern Approaches to Anti-EGFR Therapy
Владимировна, Д. Е., Nadyrova, A. I., Luginskaya, S., Kosnyrev, A. S., Владимировна, У. В., & Ilinskaya, O. N. (2025) · Molecular Biology · doi:10.1134/s0026893325700347 · Cited by 1
Oh, C. R., Lee, J., Kim, J. E., Jun, H. R., Kim, S. Y., Kim, T. W., Kim, J., Chun, S., & Hong, Y. S. (2026) · Clinical & Translational Oncology · doi:10.1007/s12094-025-04168-6 · Cited by 2
Toyokawa, E., Ooki, A., Shinozaki, E., Yoshikawa, K., Suzuki, K., Shiozawa, M., Maeda, S., Yamaguchi, K., & Osumi, H. (2026) · Biomolecules · doi:10.3390/biom16040543 · Cited by 1
Орлов, С. В., Лактионов, К. К., Musaelyan, A. A., Реутова, Е. В., Одинцова, С. В., Urtenova, M. A., Kuz'mina, V. A., Tiurin, V. I., Lomakova, A. E., & Имянитов, Е. Н. (2026) · Exploration of Targeted Anti-tumor Therapy · doi:10.37349/etat.2026.1002366 · Cited by 1
Graham, T. A. (2021) · Faculty Opinions – Post-Publication Peer Review of the Biomedical Literature · doi:10.3410/f.736145192.793584899 · Cited by 1
IMPACT OF KRAS/NRAS MUTATIONAL HETEROGENEITY ON CLINICAL OUTCOMES IN COLORECTAL CANCER
Loree, J. M. (2017) · Digital Commons-TMC (Texas Medical Center)
Precision Medicine in Metastatic Colorectal Cancer—Finding and Hitting the Right Targets
Ciombor, K. K., & Bekaii‐Saab, T. (2020) · touchREVIEWS in Oncology & Haematology · doi:10.17925/ohr.2020.16.1.36
Stellenwert der Liquid Biopsy im Rahmen der Therapie des kolorektalen Karzinoms
Baraniskin, A. (2022) · Gastro-News · doi:10.1007/s15036-022-2530-2
Metadata
- Authors
- Van Emburgh, B. O., Arena, S., Siravegna, G., Lazzari, L., Crisafulli, G., Corti, G., Mussolin, B., Baldi, F., Buscarino, M., Bartolini, A., Valtorta, E., Vidal, J., Bellosillo, B., Germano, G., Pietrantonio, F., Ponzetti, A., Albanell, J., Siena, S., Sartore-Bianchi, A., Di Nicolantonio, F., Montagut, C., & Bardelli, A.
- Affiliations
- Candiolo Cancer Institute (IT)
- Azienda Socio Sanitaria Territoriale Grande Ospedale Metropolitano Niguarda (IT)
- Hospital Del Mar (ES)
- Fondazione IRCCS Istituto Nazionale dei Tumori (IT)
- Azienda Ospedaliero Universitaria San Giovanni Battista (IT)
- University of Milan (IT)
- Corresponding author
- Montagut, Clara
- Bardelli, Alberto
- ORCID
- Venue
- Nature Communications
- Published
- 2016-12-08
- Volume
- 7
- Issue
- 1
- Pages
- 13665-13665
- ISSN
- 2041-1723 (ISSN-L)
- PMC
- PMC5155160
- OpenAlex
- W2560160922
- Cited by
- 214
- References
- 48
- Citations by year
- 2026: 15 · 2025: 10 · 2024: 16 · 2023: 24 · 2022: 30 · 2021: 24 · 2020: 24 · 2019: 29 · 2018: 23 · 2017: 17 · 2016: 1
- FWCI
- 12.59
- Type
- journal article
- Language
- en
- Open access
- gold
- doi.org
- Licence
- cc-by
- creativecommons.org/licenses/by/4.0 (tdm)
- creativecommons.org/licenses/by/4.0 (vor)
- Locations
- Nature Communications (publishedVersion, cc-by)
- PubMed Central (publishedVersion, cc-by)
- PubMed (publishedVersion)
- Archivio Istituzionale della Ricerca (Universita Degli Studi Di Milano) (submittedVersion, other-oa)
- Institutional Research Information System University of Turin (University of Turin) (submittedVersion, cc-by)
- RePEc: Research Papers in Economics (submittedVersion)
- DOAJ (DOAJ: Directory of Open Access Journals) (submittedVersion, cc-by-sa)
- Repositori digital de la UPF (Universitat Pompeu Fabra) (submittedVersion, cc-by)
- Funders
- European Commission (635342, 115749, 602901)
- Ministero della Salute
- Associazione Italiana per la Ricerca sul Cancro (16788)
- Fondazione Oncologia Niguarda Onlus
- Instituto de Salud Carlos III (RD12/0036/0051, DTS15/00048, 2014SGR740, PIE15/00008, PI15/00457, PI15/00146, 00048)
- European Regional Development Fund (PIE15/00008, PI15/00146, RD12/0036/0051)
- Topics
- Health Sciences › Medicine › Oncology › Colorectal Cancer Treatments and Studies
- Health Sciences › Medicine › Pulmonary and Respiratory Medicine › Lung Cancer Treatments and Mutations
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Cancer Research › Cancer Genomics and Diagnostics
- Keywords
- colorectal cancer, EGFR inhibition, RAS mutations, cetuximab, panitumumab, anti-EGFR monoclonal antibody, drug resistance, clonal evolution, progression-free survival, tumor shrinkage
- MeSH terms
- Antineoplastic Agents, Immunological, Adult, Aged, Aged, 80 and over, Female, Humans, Male, Middle Aged, Mutation, Genes, ras, Colorectal Neoplasms, Genes, erbB-1, Drug Resistance, Neoplasm, Clonal Evolution, ErbB Receptors
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.